JP2018501794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501794A5 JP2018501794A5 JP2017533969A JP2017533969A JP2018501794A5 JP 2018501794 A5 JP2018501794 A5 JP 2018501794A5 JP 2017533969 A JP2017533969 A JP 2017533969A JP 2017533969 A JP2017533969 A JP 2017533969A JP 2018501794 A5 JP2018501794 A5 JP 2018501794A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- car
- sequence encoding
- spacer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019206023A JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201423172 | 2014-12-24 | ||
| GB1423172.4 | 2014-12-24 | ||
| PCT/GB2015/054137 WO2016102965A1 (en) | 2014-12-24 | 2015-12-23 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019206023A Division JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501794A JP2018501794A (ja) | 2018-01-25 |
| JP2018501794A5 true JP2018501794A5 (enExample) | 2019-06-20 |
| JP6633081B2 JP6633081B2 (ja) | 2020-01-22 |
Family
ID=55066668
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533969A Active JP6633081B2 (ja) | 2014-12-24 | 2015-12-23 | 細胞 |
| JP2019206023A Active JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
| JP2020199333A Active JP7514746B2 (ja) | 2014-12-24 | 2020-12-01 | 細胞 |
| JP2021170769A Withdrawn JP2022002546A (ja) | 2014-12-24 | 2021-10-19 | 細胞 |
| JP2024032851A Pending JP2024055976A (ja) | 2014-12-24 | 2024-03-05 | 細胞 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019206023A Active JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
| JP2020199333A Active JP7514746B2 (ja) | 2014-12-24 | 2020-12-01 | 細胞 |
| JP2021170769A Withdrawn JP2022002546A (ja) | 2014-12-24 | 2021-10-19 | 細胞 |
| JP2024032851A Pending JP2024055976A (ja) | 2014-12-24 | 2024-03-05 | 細胞 |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US11091532B2 (enExample) |
| EP (3) | EP3237442B1 (enExample) |
| JP (5) | JP6633081B2 (enExample) |
| KR (6) | KR20200003939A (enExample) |
| CN (2) | CN107002045B (enExample) |
| AU (5) | AU2015370679C1 (enExample) |
| BR (1) | BR112017013690A2 (enExample) |
| CA (2) | CA2970440A1 (enExample) |
| CL (3) | CL2017001314A1 (enExample) |
| DK (2) | DK3560953T5 (enExample) |
| ES (2) | ES2744910T3 (enExample) |
| FI (1) | FI3560953T3 (enExample) |
| HR (1) | HRP20240357T1 (enExample) |
| HU (2) | HUE066020T2 (enExample) |
| IL (4) | IL301458A (enExample) |
| LT (1) | LT3560953T (enExample) |
| MX (1) | MX2017006233A (enExample) |
| PL (2) | PL3237442T3 (enExample) |
| PT (2) | PT3237442T (enExample) |
| RS (1) | RS65343B1 (enExample) |
| RU (2) | RU2768019C2 (enExample) |
| SG (2) | SG11201704084VA (enExample) |
| SI (1) | SI3560953T1 (enExample) |
| SM (1) | SMT202400134T1 (enExample) |
| WO (1) | WO2016102965A1 (enExample) |
| ZA (1) | ZA201703381B (enExample) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201415347D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| BR112017013690A2 (pt) | 2014-12-24 | 2018-03-06 | Ucl Business Plc | célula |
| SG10201913124RA (en) | 2015-02-06 | 2020-03-30 | Nat Univ Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| MY196588A (en) | 2015-03-05 | 2023-04-19 | Hutchinson Fred Cancer Res | Immunomodulatory Fusion Proteins and uses Thereof |
| CA2981751A1 (en) * | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
| GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| WO2016210293A1 (en) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| GB201610515D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| JP7114490B2 (ja) * | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| WO2018045325A1 (en) * | 2016-09-02 | 2018-03-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| CN110225927B (zh) | 2016-10-07 | 2024-01-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
| CN110268049B (zh) | 2016-11-22 | 2024-06-14 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| IL266892B2 (en) | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| EP3556772A4 (en) * | 2016-12-13 | 2020-09-09 | Carsgen Therapeutics Ltd | HUMANIZED ANTI-CD19 ANTIBODY AND TARGETING IMMUNE EFFICIENT CELL CD19 |
| US20190336533A1 (en) * | 2016-12-28 | 2019-11-07 | Green Cross Lab Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CN110621335B (zh) | 2017-03-17 | 2025-06-03 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| JP7505885B2 (ja) * | 2017-04-14 | 2024-06-25 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
| US20200048618A1 (en) * | 2017-04-18 | 2020-02-13 | Autolus Limited | Cell |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CA3062433A1 (en) * | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| SG10202109108UA (en) | 2017-06-21 | 2021-09-29 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| SG11202000402PA (en) | 2017-08-10 | 2020-02-27 | Nat Univ Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN109385402A (zh) * | 2017-08-11 | 2019-02-26 | 上海恒润达生生物科技有限公司 | 一种等比例混合两种靶点cart细胞的制备方法及应用 |
| CN107446937B (zh) * | 2017-09-05 | 2020-12-25 | 深圳华云生物技术有限公司 | 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用 |
| JP7654240B2 (ja) | 2017-09-19 | 2025-04-01 | マサチューセッツ インスティテュート オブ テクノロジー | キメラ抗原受容体ｔ細胞治療のための組成物およびその使用 |
| EP3697426B1 (en) | 2017-10-16 | 2023-07-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd22 immunotherapy |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109988242A (zh) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | 联合嵌合抗原受体、表达载体、慢病毒及t细胞 |
| CN108101994B (zh) * | 2018-01-04 | 2020-09-15 | 广东万海细胞生物科技有限公司 | 抗cd19抗体及其应用 |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| EP3752170A4 (en) * | 2018-02-12 | 2022-03-30 | The General Hospital Corporation | CHEMERA ANTIGEN RECEPTORS TARGETING THE MICROENVIRONMENT |
| CN110157738B (zh) * | 2018-02-13 | 2023-06-27 | 亘喜生物科技（上海）有限公司 | 靶向cd19和cd22的工程化免疫细胞及其应用 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| US11963981B2 (en) | 2018-05-15 | 2024-04-23 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| WO2019226945A1 (en) | 2018-05-23 | 2019-11-28 | National University Of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US20210275589A1 (en) * | 2018-07-13 | 2021-09-09 | Nanjing Legend Biotech Co. Ltd. | Co-receptor systems for treating infectious diseases |
| JP7458382B2 (ja) | 2018-09-27 | 2024-03-29 | オートラス リミテッド | キメラ抗原受容体 |
| US20200102370A1 (en) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| GB201816522D0 (en) | 2018-10-10 | 2018-11-28 | Autolus Ltd | Methods and reagents for analysing nucleic acids from single cells |
| GB201820547D0 (en) | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| SG11202112536UA (en) * | 2019-05-16 | 2021-12-30 | Nanjing Legend Biotech Co Ltd | Engineered immune cells comprising a recognition molecule |
| WO2020247837A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| JP2022536364A (ja) | 2019-06-13 | 2022-08-15 | ザ ジェネラル ホスピタル コーポレイション | 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 |
| JP2022538974A (ja) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | 免疫調節融合タンパク質－金属水酸化物錯体およびその方法 |
| GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
| US20220257757A1 (en) | 2019-07-16 | 2022-08-18 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| CN114929738B (zh) | 2019-08-07 | 2026-01-02 | 水肺治疗公司 | 抗nampt抗体及其用途 |
| CN112390891B (zh) * | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
| CN110903401A (zh) * | 2019-11-20 | 2020-03-24 | 浙江大学 | 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用 |
| IL292924A (en) * | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| WO2021158534A1 (en) * | 2020-02-04 | 2021-08-12 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells |
| WO2021180890A1 (en) * | 2020-03-11 | 2021-09-16 | Fundació Institut De Recerca Contra La Leucèmia Josep Carreras | Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all) |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| CA3187267A1 (en) | 2020-06-17 | 2021-12-23 | Janssen Biotech, Inc. | Materials and methods for the manufacture of pluripotent stem cells |
| KR20230043151A (ko) | 2020-07-24 | 2023-03-30 | 더 제너럴 하스피탈 코포레이션 | 증강된 바이러스-유사 입자 및 세포에의 전달을 위한 그의 사용 방법 |
| TW202216754A (zh) * | 2020-08-25 | 2022-05-01 | 美商賽特免疫治療公司 | 雙特異性抗體car細胞免疫療法 |
| MX2023006395A (es) | 2020-12-03 | 2023-06-15 | Century Therapeutics Inc | Celulas dise?adas geneticamente y usos de estas. |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| KR102393776B1 (ko) * | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| IL305411A (en) * | 2021-02-26 | 2023-10-01 | Kelonia Therapeutics Inc | Lymphocyte targeted lentiviral vectors |
| US20230174651A1 (en) | 2021-06-23 | 2023-06-08 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
| WO2023016554A1 (zh) * | 2021-08-13 | 2023-02-16 | 上海医药集团股份有限公司 | 靶向cd22的抗原结合蛋白及其用途 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| EP4522204A1 (en) | 2022-05-11 | 2025-03-19 | Autolus Limited | Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia |
| CA3262611A1 (en) | 2022-07-22 | 2024-01-25 | Janssen Biotech, Inc. | IMPROVED TRANSFER OF GENETIC INSTRUCTIONS TO EFFECTOR IMMUNE CELLS |
| WO2024137508A1 (en) * | 2022-12-19 | 2024-06-27 | Development Center For Biotechnology | Chimeric antigen receptors, nucleic acids encod ing the same, and uses thereof in treating cancers |
| WO2024196796A1 (en) * | 2023-03-17 | 2024-09-26 | Cartesian Therapeutics, Inc. | Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors |
| WO2024246526A1 (en) | 2023-05-30 | 2024-12-05 | Autolus Limited | Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia |
| WO2024250037A1 (en) * | 2023-06-02 | 2024-12-05 | Northeastern University | Targeted immune cell therapy utilizing trail and tnf mediated apoptosis |
| WO2025088308A1 (en) | 2023-10-23 | 2025-05-01 | Autolus Limited | Products and methods for treating autoimmune diseases |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| WO2025215360A1 (en) | 2024-04-09 | 2025-10-16 | Autolus Limited | Method |
| WO2025231185A1 (en) | 2024-05-01 | 2025-11-06 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
| WO2025259108A1 (en) | 2024-06-11 | 2025-12-18 | Prinses Máxima Centrum Voor Kinderoncologie B.V. | Brain organoid |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2299011A1 (fr) | 1975-01-29 | 1976-08-27 | Obert Jean Claude | Generateur d'aerosols de part |
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| ATE338124T1 (de) * | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| WO2004106381A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| RS53905B1 (sr) | 2005-12-16 | 2015-08-31 | Amgen Research (Munich) Gmbh | Metode i sredstva za lečenje tumorskih bolesti |
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| BR112014008849A2 (pt) * | 2011-10-20 | 2017-09-12 | Us Health | receptores quiméricos de antígeno anti-cd22 |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN104583230A (zh) | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | 通过共同引入双特异性抗体增强car t细胞的活性 |
| JP6441802B2 (ja) | 2012-10-02 | 2018-12-19 | メモリアル スローン ケタリング キャンサー センター | 免疫療法のための組成物および方法 |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US10072078B2 (en) * | 2012-10-24 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | M971 chimeric antigen receptors |
| ES2748398T3 (es) * | 2013-02-06 | 2020-03-16 | Celgene Corp | Linfocitos T modificados con especificidad mejorada |
| WO2014138704A1 (en) | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
| MX386060B (es) | 2013-03-15 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Composiciones y usos para inmunoterapia. |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| HUE067258T2 (hu) | 2013-05-13 | 2024-10-28 | Cellectis | CD19-re specifikus kiméra antigénreceptor és alkalmazásai |
| US10279009B2 (en) | 2013-07-18 | 2019-05-07 | Baylor College Of Medicine | Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy |
| ES2832586T3 (es) * | 2013-11-21 | 2021-06-10 | Autolus Ltd | Célula |
| US10239948B2 (en) | 2013-12-20 | 2019-03-26 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
| BR112017013690A2 (pt) | 2014-12-24 | 2018-03-06 | Ucl Business Plc | célula |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201507111D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| WO2016210293A1 (en) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| US11963981B2 (en) | 2018-05-15 | 2024-04-23 | Autolus Limited | Chimeric antigen receptor |
-
2015
- 2015-12-23 BR BR112017013690-2A patent/BR112017013690A2/pt not_active Application Discontinuation
- 2015-12-23 KR KR1020197038792A patent/KR20200003939A/ko not_active Ceased
- 2015-12-23 SG SG11201704084VA patent/SG11201704084VA/en unknown
- 2015-12-23 PL PL15817520T patent/PL3237442T3/pl unknown
- 2015-12-23 PT PT15817520T patent/PT3237442T/pt unknown
- 2015-12-23 EP EP15817520.8A patent/EP3237442B1/en not_active Revoked
- 2015-12-23 SM SM20240134T patent/SMT202400134T1/it unknown
- 2015-12-23 ES ES15817520T patent/ES2744910T3/es active Active
- 2015-12-23 KR KR1020217024459A patent/KR102376244B1/ko active Active
- 2015-12-23 IL IL301458A patent/IL301458A/en unknown
- 2015-12-23 DK DK19172397.2T patent/DK3560953T5/da active
- 2015-12-23 IL IL292508A patent/IL292508B2/en unknown
- 2015-12-23 IL IL274903A patent/IL274903B/en unknown
- 2015-12-23 CA CA2970440A patent/CA2970440A1/en active Pending
- 2015-12-23 PT PT191723972T patent/PT3560953T/pt unknown
- 2015-12-23 RU RU2017121892A patent/RU2768019C2/ru active
- 2015-12-23 HR HRP20240357TT patent/HRP20240357T1/hr unknown
- 2015-12-23 HU HUE19172397A patent/HUE066020T2/hu unknown
- 2015-12-23 LT LTEP19172397.2T patent/LT3560953T/lt unknown
- 2015-12-23 PL PL19172397.2T patent/PL3560953T3/pl unknown
- 2015-12-23 RU RU2022102250A patent/RU2022102250A/ru unknown
- 2015-12-23 US US15/529,690 patent/US11091532B2/en active Active
- 2015-12-23 DK DK15817520.8T patent/DK3237442T3/da active
- 2015-12-23 JP JP2017533969A patent/JP6633081B2/ja active Active
- 2015-12-23 CN CN201580065695.4A patent/CN107002045B/zh active Active
- 2015-12-23 AU AU2015370679A patent/AU2015370679C1/en active Active
- 2015-12-23 KR KR1020227031979A patent/KR20220129684A/ko not_active Ceased
- 2015-12-23 EP EP19172397.2A patent/EP3560953B1/en active Active
- 2015-12-23 MX MX2017006233A patent/MX2017006233A/es active IP Right Grant
- 2015-12-23 EP EP23217769.1A patent/EP4368704A3/en active Pending
- 2015-12-23 CA CA3224507A patent/CA3224507A1/en active Pending
- 2015-12-23 SG SG10202111107RA patent/SG10202111107RA/en unknown
- 2015-12-23 RS RS20240357A patent/RS65343B1/sr unknown
- 2015-12-23 KR KR1020177019393A patent/KR102085349B1/ko active Active
- 2015-12-23 CN CN202111208410.1A patent/CN114107212A/zh active Pending
- 2015-12-23 KR KR1020237036909A patent/KR20230152824A/ko active Pending
- 2015-12-23 WO PCT/GB2015/054137 patent/WO2016102965A1/en not_active Ceased
- 2015-12-23 KR KR1020217024458A patent/KR102376242B1/ko active Active
- 2015-12-23 ES ES19172397T patent/ES2976197T3/es active Active
- 2015-12-23 SI SI201531999T patent/SI3560953T1/sl unknown
- 2015-12-23 FI FIEP19172397.2T patent/FI3560953T3/fi active
- 2015-12-23 HU HUE15817520A patent/HUE046262T2/hu unknown
-
2017
- 2017-05-10 IL IL252208A patent/IL252208B/en unknown
- 2017-05-16 ZA ZA2017/03381A patent/ZA201703381B/en unknown
- 2017-05-23 CL CL2017001314A patent/CL2017001314A1/es unknown
- 2017-06-23 US US15/631,948 patent/US10098926B2/en active Active
- 2017-06-23 US US15/632,119 patent/US10174099B2/en active Active
-
2018
- 2018-06-29 US US16/024,445 patent/US10981970B2/en active Active
- 2018-11-13 CL CL2018003216A patent/CL2018003216A1/es unknown
- 2018-11-13 CL CL2018003217A patent/CL2018003217A1/es unknown
- 2018-12-06 US US16/211,538 patent/US11034750B2/en active Active
-
2019
- 2019-11-14 JP JP2019206023A patent/JP6909844B2/ja active Active
-
2020
- 2020-02-07 US US16/785,467 patent/US20200181232A1/en not_active Abandoned
- 2020-08-06 AU AU2020213352A patent/AU2020213352B2/en active Active
- 2020-12-01 JP JP2020199333A patent/JP7514746B2/ja active Active
-
2021
- 2021-10-19 JP JP2021170769A patent/JP2022002546A/ja not_active Withdrawn
-
2022
- 2022-07-12 AU AU2022205169A patent/AU2022205169B2/en active Active
- 2022-07-12 AU AU2022205170A patent/AU2022205170B2/en active Active
-
2023
- 2023-01-24 US US18/158,754 patent/US12398194B2/en active Active
-
2024
- 2024-03-05 JP JP2024032851A patent/JP2024055976A/ja active Pending
- 2024-12-10 AU AU2024278248A patent/AU2024278248A1/en active Pending
-
2025
- 2025-07-25 US US19/281,399 patent/US20250353893A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501794A5 (enExample) | ||
| RU2017121892A (ru) | Клетка | |
| JP7578938B2 (ja) | Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用 | |
| EP3847195B1 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| JP2016538855A5 (enExample) | ||
| JP2017500869A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| JP2017508466A5 (enExample) | ||
| US11970545B2 (en) | T cell-antigen coupler with Y182T mutation and methods of uses thereof | |
| CN108138148B (zh) | T细胞的激活和扩增 | |
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| JP2018508215A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| JP2016538854A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| BR112021008082A2 (pt) | terapia contra o câncer com células imunitárias anti-liv1 | |
| CN120500501A (zh) | 用于治疗癌症的细胞和组合物 | |
| JP2022514815A (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| CN110950957B (zh) | 可结合ctla4的多肽及其应用 | |
| KR20230025655A (ko) | 암 치료용 조성물 및 방법 | |
| CN108484778B (zh) | 人源化ghr106单克隆抗体的嵌合抗原受体构建体及核酸分子与应用 | |
| CN114685659B (zh) | Cd22特异性人源化抗体及利用其的嵌合抗原受体 | |
| CN110950956B (zh) | 可结合pd1的多肽及其应用 | |
| EP4656659A1 (en) | Modified fc-engagers for treating immune diseases | |
| JPWO2023020558A5 (enExample) |